MedTrace Logo

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

NCT03158064 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-28

No results posted yet for this study

Summary

The purpose of this study is to test the safety and effectiveness of durvalumab with tremelimumab in patients with relapsed or refractory germ cell tumors.

Conditions

  • Germ Cell Tumor
  • Nonseminomatous Germ Cell Tumor
  • Seminoma
  • Germinomatous Germ Cell Tumor
  • Dysgerminoma
  • Pineal Germ Cell Tumor

Interventions

DRUG

Durvalumab

1500 mg by IV

DRUG

Tremelimumab

75 mg by IV \*300mg

Sponsors & Collaborators

Principal Investigators

  • Samuel Funt, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2026-11-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03158064 on ClinicalTrials.gov